Geller, J. I., Perentesis, J. P., Liu, X., Minard, C. G., Kudgus, R. A., Reid, J. M., . . . Weigel, B. J. (2017). A Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ197) in Children with Relapsed or Refractory Solid Tumors: A Children’s Oncology Group Study Phase 1 and Pilot Consortium Trial (ADVL1111). Pediatr Blood Cancer.
استشهاد بنمط شيكاغوGeller, James I., John P. Perentesis, Xiaowei Liu, Charles G. Minard, Rachel A. Kudgus, Joel M. Reid, Elizabeth Fox, Susan M. Blaney, و Brenda J. Weigel. "A Phase 1 Study of the C-Met Inhibitor, Tivantinib (ARQ197) in Children With Relapsed or Refractory Solid Tumors: A Children’s Oncology Group Study Phase 1 and Pilot Consortium Trial (ADVL1111)." Pediatr Blood Cancer 2017.
MLA استشهادGeller, James I., et al. "A Phase 1 Study of the C-Met Inhibitor, Tivantinib (ARQ197) in Children With Relapsed or Refractory Solid Tumors: A Children’s Oncology Group Study Phase 1 and Pilot Consortium Trial (ADVL1111)." Pediatr Blood Cancer 2017.